Abstract:Abstract The recent outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 infection in Wuhan, China has posed a serious threat to global public health. To develop specific anti-coronavirus therapeutics and prophylactics, the molecular mechanism that underlies viral infection must first be defined. Therefore, we herein established a SARS-CoV-2 spike (S) protein-mediated cell–cell fusion assay and found that SARS-CoV-2 showed a superior plasma membrane fusion capacity compared to that of SARS-CoV. We solved the X-ray crystal structure of six-helical bundle (6-HB) core of the HR1 and HR2 domains in the SARS-CoV-2 S protein S2 subunit, revealing that several mutated amino acid residues in the HR1 domain may be associated with enhanced interactions with the HR2 domain. We previously developed a pan-coronavirus fusion inhibitor, EK1, which targeted the HR1 domain and could inhibit infection by divergent human coronaviruses tested, including SARS-CoV and MERS-CoV. Here we generated a series of lipopeptides derived from EK1 and found that EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC50s of 1.3 and 15.8 nM, about 241- and 149-fold more potent than the original EK1 peptide, respectively. EK1C4 was also highly effective against membrane fusion and infection of other human coronavirus pseudoviruses tested, including SARS-CoV and MERS-CoV, as well as SARSr-CoVs, and potently inhibited the replication of 5 live human coronaviruses examined, including SARS-CoV-2. Intranasal application of EK1C4 before or after challenge with HCoV-OC43 protected mice from infection, suggesting that EK1C4 could be used for prevention and treatment of infection by the currently circulating SARS-CoV-2 and other emerging SARSr-CoVs.

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core.

Characterization of the Heptad Repeat Regions, HR1 and HR2, and Design of a Fusion Core Structure Model of the Spike Protein from Severe Acute Respiratory Syndrome (SARS) Coronavirus.

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Construct Design, Biophysical, and Biochemical Characterization of the Fusion Core from Mouse Hepatitis Virus (a Coronavirus) Spike Protein

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin

Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor

Nanometer-resolution in situ structure of the SARS-CoV-2 postfusion spike protein

Characterization of Hcov-229e Fusion Core: Implications for Structure Basis of Coronavirus Membrane Fusion

Nanometer resolution in situ structure of SARS-CoV-2 post-fusion spike

Designed peptides as potential fusion inhibitors against SARA-CoV-2 coronavirus infection

Spike protein mediated membrane fusion during SARS‐CoV‐2 infection

In situ architecture and membrane fusion of SARS-CoV-2 Delta variant

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Following the Rule: Formation of the 6-Helix Bundle of the Fusion Core from Severe Acute Respiratory Syndrome Coronavirus Spike Protein and Identification of Potent Peptide Inhibitors.

Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation

Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy

Structure-based Discovery of Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor